Lens extraction should be considered for PACG

Article

Lens extraction for PACG results in good long-term control of IOP, and should be considered among the armamentarium of approaches to treat PACG.

Lens extraction for primary angle-closure glaucoma (PACG) results in good long-term control of intraocular pressure (IOP), and should be considered among the armamentarium of approaches to treat PACG - especially for patients who have hyperopia, or a thick and anteriorly vaulted lens, according to a report in Current Opinion in Ophthalmology.

The authors of the report note that anatomical opening of the angle, IOP reduction, and improved vision are all benefits cited by proponents of lens extraction in PACG.

The evidence base for ophthalmic surgeons to consider lens extraction in the management of PACG has grown stronger recently thanks to randomized controlled trials, case-control studies and cohort studies. Such studies have also added to the discussion of whether trabeculectomy or goniosynechialysis should be combined with lens extraction.

New insights have also been gained thanks to imaging modalities, such as anterior segment optical coherence tomography, that are providing information on the mechanical features of the lens in angle closure. For example, lens thickness and lens vault are now quantifiable.

“A trend is emerging regarding the improvement in IOP control, reduced complication rates and reduced need for IOP-lowering medications in patients who undergo lens extraction for PACG,” the authors state.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.